Asthma Drugs Market Scope And Analysis

  • Report Code : TIPRE00021879
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Asthma Drugs Market Analysis, Trends, and Scope 2022 to 2028

Buy Now

Asthma Drugs Market Report Asthma Drugs Market Size and Share Asthma Drugs Market Scope and Analysis

Asthma Drugs Market Report Scope

Report Attribute Details
Market size in 2023 US$ 26.72 Billion
Market Size by 2031 US$ 39.48 Billion
Global CAGR (2023 - 2031) 5.00%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Medications
  • Quick Relief Medications and Long-Term Control Medications
By Route of Administration
  • Inhaled
  • Prefilled Syringes/Vials
By Distribution Channels
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • AstraZeneca
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Merck Co Inc
  • Koninklijke Philips NV
  • Sanofi
  • Pfizer Inc
  • Novartis AG
    		•

    Asthma Drugs Market News and Recent Developments

    The asthma drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the asthma drugs market are listed below:

    • GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. (Source: GSK plc, Press Release, February 2024)
    • Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc. announced a clinical collaboration agreement to accelerate further the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle, also announced a strategic development funding agreement in which Abingworth provides Teva up to US$ 150 million to offset Teva’s ICS/SABA (TEV-‘248) program costs. The collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program. (Source: Teva Pharmaceutical, Press Release, April 2024)

    Asthma Drugs Market Report Coverage and Deliverables

    The “Asthma Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Asthma drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Asthma drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Asthma drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the asthma drugs market
    • Detailed company profiles